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This study was designed to test the hypothesis that 60 days continuous head down bed 
rest (HDBR), an Earth-based analogue of the effects of space flight, would elevate factors 
that increase vasoconstriction and would increase markers of vascular inflammation.  The 
study incorporated countermeasures consisting of treadmill running within lower-body 
negative pressure and resistive “flywheel” exercise (exercise countermeasure, EX) or an 
increased protein intake of 0.6 g/kg body weight/day (dietary countermeasures, DIET) to 
determine whether these interventions might prevent the vasoconstrictor and 
inflammatory responses when compared to a control (CON) group.  Markers of vascular 
health measured in the study include the vasoactive molecules angiotensin II (Ang II), 
endothelin-1 (ET-1), and nitric oxide metabolites (NOmet); and markers of inflammation 
including C-reactive protein (CRP), and the adhesion molecules E-selectin (E-sel), 
intracellular adhesion molecule-1 (ICAM), and vascular cell adhesion molecule-1 
(VCAM).  Twenty four women were housed at the MEDES clinic in Toulouse, France, as 
part of a large international study (Women International Space Simulation for 
Exploration, WISE) in which various experimental protocols and countermeasures were 
integrated into a single experimental design completed during two campaigns.  Each 100 
day campaign included 20 days of pre-testing (pre-HDBR), 60 days of bed rest (HDBR), 
and 20 days of post-testing (post-HDBR).  The experimental countermeasures were 
applied only during the 60-day HDBR period.  Following 60 days of HDBR, many 
changes occurred in the concentrations of the measured molecules.  Specifically, the 
concentration of Ang II significantly increased in the CON and DIET groups (52.9%, p = 
0.014; and 124.4%, p <0.0001 respectively), but not in the EX group.  Also, NOmet 
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decreased in all groups, with reductions in the EX and DIET groups (p = 0.013, and p = 
0.056 respectively).  Markers used to assess vascular inflammation increased following 
the HDBR.  The increase in CRP in the CON and DIET groups and the decrease in the 
EX group from pre- to post-HDBR were not significant; however, the directional changes 
resulted in an interaction between group and HDBR (p = 0.052).  The adhesion molecule 
E-sel was significantly increased in the DIET group (p = 0.003), and VCAM was 
significantly increased in the CON group (p = 0.016) with a smaller increase in the DIET 
group (p = 0.08).  No changes in adhesion molecules were observed in the EX group.  
This study demonstrated that 60 days of HDBR by young, healthy, women caused 
changes in several different molecules that are beginning to emerge as risk factors for the 
development of cardiovascular diseases.  Further, it was observed that regular, vigorous 
exercise during HDBR prevented these changes.  These results suggest that future studies 
of this kind should directly monitor the effects of simulated space flight on vascular 
health in men and women to obtain a greater understanding of the adaptations that might 
occur during long term space exploration missions.  HDBR can be considered an extreme 
model of physical inactivity and could be used to provide insight into mechanisms of 
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1 Literature Review 
1.1 Head Down Bed Rest 
Head down bed rest (HDBR) has been used as a model of simulated microgravity to 
determine the physiologic changes (deconditioning) that might occur with actual space 
flight.  Prior to World War II there were few bed rest studies, and of the few there were, 
most examined the use of bed rest in the treatment of different chronic diseases (Barry et 
al., 1998).  Following the advent of manned space flights, scientists were interested in 
determining the reasons for the so-called orthostatic intolerance that often affected 
astronauts upon their return to earth.  Orthostatic intolerance occurs when the 
cardiovascular system can no longer sustain adequate brain blood flow to maintain 
consciousness.  Following prolonged bed rest, mal-adaptations occur that cause 
orthostatic intolerance.   
Microgravity of space travel refers to the free-fall environment that places very 
little net gravitational force on an object.  Bed rest studies mimic many of the 
physiological changes that occur in the microgravity of space because lying down places 
the body in a recumbent position with the loss of the normal head-to-foot gravity vector.  
Thus, the hydrostatic pressure that normally elevates blood pressure in the vessels below 
the heart, and that increases forces causing longitudinal compression on the spine and 
bones of the lower limbs, has been removed.  Also, without the need to work against 
gravity, the muscular force acting on most of the bones in the body is reduced, as is the 
total energy expenditure (Convertino et al., 1997).  These changes allow the body to 
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adapt to stimuli that are similar to what astronauts experience in space (at a fraction of 
what it costs to send someone there).   
One consistent finding regarding HDBR is that there is a loss of plasma volume 
that can be countered by exercise during bed rest (Greenleaf, 1997; Belin de Chantemele et 
al., 2004).  In fact, as little as one single bout of intense exercise before resuming an 
upright position can restore the lost volume (Convertino, 1997).  Reduced plasma volume 
is the result of shifting of fluids between the intravasculature and extravascular spaces.  
Upon transition from a vertical to horizontal position part of the hydrostatic force in the 
vascular system, which is also the driving force for net filtration, is lost.  As a result, net 
reabsorption is favored and fluid shifts towards the vascular compartment (Greenleaf, 
1997).  In an attempt to control plasma volume and tonicity, fluid is excreted by the 
kidney and a state of relative hypovolemia is established as soon as a few days after the 
beginning of HDBR (Bestle et al., 2001; Trappe et al., 2006).  The new homeostatic set 
point of plasma volume usually occurs with a concomitant reduction in red cell volume 
so as to maintain the normal blood hematocrit (Convertino, 1997).    
1.1.1 Physiological Responses (Deconditioning) 
Bed rest following cardiovascular events or with many chronic diseases has, in the past, 
been a common prescription by many health care providers (Friedberg, 1966).  It is now 
known that while rest is needed, extended bed rest for patients can be detrimental to the 
recovery process due to the deconditioning that can occur (Winslow, 1985).  
Deconditioning affects the cardiovascular system as much as it affects any other system 
of the body.  When a person moves from a horizontal to vertical position (from lying to 
standing), blood begins to pool in the lower limbs due to gravity and the compliant nature 
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of the vasculature.  In order to prevent a loss of consciousness due to lack of blood 
reaching the brain, the body makes adjustments to maintain mean arterial pressure 
(MAP).  MAP is the product of cardiac output (Q) and total peripheral resistance (TPR) 
(Equation 1).  
MAP = Q x TPR Equation 1  
Q = HR x SV    Equation 2 
4r
LR ⋅∝ η   Equation 3 
MAP is mean arterial blood pressure (mmHg), Q is cardiac output (l/min),  
HR is heart rate (beats/min), SV is stroke volume (ml/beat), TPR is total peripheral 
resistance (mmHg/l/min), R is the resistance to flow (arbitrary resistance units), η is 
viscosity of the liquid (dyne-seconds/cm2), L is the length of the tube (cm), and r is the 
radius of the tube (cm). 
  Equation 1 shows that MAP is the product of Q and TPR.  The pooling of blood 
reduces the amount of blood returning to the heart (venous return).  This causes a great 
reduction in stroke volume (SV) because with less blood returning to the heart, there is 
less to eject, and a decrease in Q results (Equation 2).  This in turn causes a drop in MAP 
(Equation 1). 
A drop in MAP causes unloading of the arterial baroreceptors which mediates an 
immediate reduction in vagal tone (causing an increase in HR) in an attempt to restore Q.  
The unloading of the arterial baroreceptors also increases sympathetic outflow (SNA) 
causing peripheral vasoconstriction, increased HR, and contractility via norepinephrines 
(NE) interactions with α-receptors on blood vessels and β-receptors in the heart.  The 
peripheral vasoconstriction increases TPR in order to restore MAP (from Equation 1) and 
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the increased HR and contractility to try and compensate for Q.  The overall result is 
maintenance of MAP (Rowell, 1993). 
The events outlined above occur every time a person moves from a lying or sitting 
position to standing.  If these actions are not employed, the amount of blood returning to 
the heart would quickly decrease, and the amount of blood reaching the brain would not 
be sufficient to maintain consciousness.  Luckily, the orthostatic mechanisms outlined 
occur so often that they can be thought of as a form of orthostatic training for the blood 
vessels, nerves, and other tissues.  In HDBR, these stimuli are no longer present.  In the 
head-down position, blood is localized in the thoracic core, resulting in less blood in the 
periphery.  This in turn results in blood readily returning to the heart, and no need for the 
orthostatic mechanisms outlined above.  This lack of use by the peripheral blood vessels 
was seen by Shoemaker et al., (1998a) who showed a decrease in the vasoreactivity of 
the forearm blood vessels following 14 days of HDBR.  Shoemaker et al. (1998a) 
attributed some of the change to alterations in the SNA, which is also commonly seen in 
HDBR (Shoemaker et al., 1998a; Shoemaker et al., 1998b; Kamiya et al., 2000a).   
Changes in vascular tone result in changes in the diameter of the lumen of the 
blood vessel, and can have dramatic effects on blood pressure.  Poiseuille’s law 
(Equation 3) dictates that the resistance of a tube (in this case a blood vessel) is inversely 
proportional to the radius to the fourth power. 
If the balance between vasoconstriction and vasodilation were tipped in favor of 
one side, even a small increase (or decrease) in the radius would have a large effect on 
the resistance in that vascular bed.  Referring back to Equation 1, an increase in TPR (or 
R in Equation 3), without a reduction in Q, would lead to an increase in MAP.  
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Therefore, small changes in the radius of a blood vessel (the vascular tone) can have a 
large impact on MAP. 
Changes in the periphery are not the only adaptations that occur with HDBR.  In 
the recumbent position, the heart does not have to pump blood against the same 
hydrostatic forces as it does in a normal (vertical) position.  This results in the heart not 
having to pump as hard in order to move the same amount of blood, and as a result there 
is a reduction in ventricular muscle mass (atrophy).  Following six weeks of HDBR 
Perhonen et al., (2001) found an 8% drop in left ventricle mass as measured by MRI.  
Perhonen et al., (2001)  also found a 14% decrease in the left ventricular end-diastolic 
volume after just two weeks of HDBR.  With the reduction in SNA, and therefore less 
NE to act on β-receptors, the contractility of the heart should also decrease.  
Some of the changes seen in the cardiovascular system are due to altered physical 
stresses placed on the body by HDBR.  In the same way that our bodies will adapt to 
demands placed on it by increased physical activity (exercise), our bodies will also adapt 
to the lack of demands placed on it by increased physical inactivity.  Changes in blood 
flow and blood flow distribution can alter the stresses placed on the walls of the 
vasculature.  This can change the expression of many genes that are important to the 
function of the vasculature (Malek et al., 1999).  Altered gene expression can change the 
concentration of various molecules in the blood that can act as markers of vascular 
health.  Many of these vascular molecules are becoming recognized as potential risk 
factors for cardiovascular disease, and a lot of research is being done to determine if 
abnormal concentrations of these molecules can predispose a person to (or predict future) 
cardiovascular disease. 
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1.2 Emerging risk factors 
One large area of research revolves around the search for factors in the blood that can act 
as early markers or flags for cardiovascular disease (Hwang et al., 1997; Böger et al., 
1998; Blankenberg et al., 2003; Vallance and Leiper, 2004).  The rationale is that if a 
simple blood test can detect abnormal levels of these markers early (before the 
cardiovascular disease develops), prevention and treatment strategies can be implemented 
sooner.  Many of these markers are found in normal healthy individuals, however, in 
patients with established cardiovascular disease the concentrations of these markers are 
thought to change (de Ferranti and Rifai, 2002; Hackam and Anand, 2003; Szmitko et al., 
2003a; Szmitko et al., 2003b).  It is the early changes in these markers that will allow 
researchers and health care practitioners to determine if a person is at risk for developing 
cardiovascular disease. 
While looking for a marker that will allow doctors and researchers to predict 
cardiovascular disease seems promising, it may be more pertinent at this time to examine 
the health of the vascular system, and how the makeup of plasma can interact with the 
vessels to either promote or curb disease.  Many of the aforementioned risk factors play 
important physiologic roles in the vasculature.  When the concentration of these factors 
change, it may be an early indication of a much bigger problem.  These factors fall into 
different categories, and two of the most important ones have been determined to be 
vasoactive molecules and inflammatory markers. 
1.2.1 Vasoactive Molecules 
Substances that cause blood vessels to either dilate or constrict are termed vasoactive 
substances and play a key role in regulating blood flow distribution, and blood pressure 
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(Kohno et al., 1990; Skarphedinsson et al., 1997; Kranzhofer et al., 1999).  Some 
common vasoactive substances include angiotensin II (Ang II), endothelin-1 (ET-1), 
norepinephrine (NE), and nitric oxide (NO).  These molecules all have many actions (and 
target tissues), however, it is the interaction of these molecules with tissues of the 
vascular system that modulate vascular tone, cell growth, proliferation, and vascular 
health in general (Kranzhofer et al., 1999; Williams, 2001; de Gasparo, 2002; Alonso and 
Radomski, 2003). 
The classical view of Ang II pertains to its role as the effector molecule in the 
renin-angiotensin system (RAS), which is integral in the long term control of blood 
pressure (Hahn et al., 1993).  In this system, renin is released from the kidney in response 
to renal hypotension, reduced sodium delivery to the distal tubule, and reduced renal 
sympathetic innervation (RSNA) (Schweda and Kurtz, 2004).  Renin then acts to convert 
angiotensinogen into Ang I.  Angiotensin converting enzyme (ACE) then converts Ang I 
into the biologically active Ang II.  Ang II stimulates the release of aldosterone from the 
adrenal cortex which causes the reabsorption of sodium, and therefore H2O (Kato et al., 
1993).  Ang II has two receptors: AT1and AT2.  AT1 is a member of the G-protein family 
of receptors; it is highly expressed on vascular smooth muscle cells and has been shown 
to mediate many of the additional physiological functions of Ang II (Sadoshima, 1998).  
These functions include vasoconstriction, cell growth, and proliferation.  The AT2 
receptor is mainly found in fetal tissues, however, its expression decreases rapidly after 
birth.  The functions of the AT2 receptor are unclear, but they appear to antagonize the 
actions of the AT1 receptor by inhibiting cell growth, inducing apoptosis, and causing 
vasodilatation (Touyz and Schiffrin, 2000).  
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The role of RAS in controlling blood pressure is of central importance in the 
development of many cardiovascular diseases, as hypertension is a major risk factor for 
cardiovascular disease (Unger, 2002).  When Ang II binds to AT1 many of the effects that 
are signaled appear to increase cardiovascular disease.  For example, increased 
vasoconstriction can lead to hypertension, vascular smooth muscle activation (leading to 
cell proliferation and migration), and endothelial cell activation (causing increased 
expression of adhesion molecules–discussed later) (Kranzhofer et al., 1999; Williams, 
2001).  Experimentally, exercise training protocols have been shown to increase the 
concentration of Ang II initially, however, the concentration usually returns back to 
baseline after a few weeks (Warburton et al., 2004).   
One of the most potent vasoactive substances known is the vasoconstrictive ET-1.  
ET-1 is produced in endothelial cells in response to humoral factors such as Ang II and 
arginine vasopressin, and is also controlled by shear and stretch factors acting on 
endothelial cells (Modesti, 1996).  ET-1 has two receptors, ETA and ETB.  Both receptor 
types are expressed on vascular smooth muscle cells, and when either has ET-1 bound, 
vasoconstriction occurs.  ETB is also expressed on endothelial cells and when ET-1 binds 
to this receptor it stimulates the release of NO (Modesti, 1996).   
ET-1 production is enhanced in patients with moderate-to-severe hypertension 
and also in persons with developed atherosclerosis (Kohno et al., 1990; Lerman et al., 
1995).  Much like Ang II, ET-1 is thought to play a role in the development of 
hypertension, vascular smooth muscle cell activation, and endothelial cell activation 
(Schiffrin, 2001).   
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 ET-1 not only acts as a vasoconstrictor, but like Ang II, it also stimulates vascular 
smooth muscle cell growth and cell adhesion (Alonso and Radomski, 2003).  In this 
regard, increased concentrations of Ang II and ET-1 are thought to be harmful to the 
vasculature in that they can stimulate inflammatory processes, aid in vascular 
remodeling, and can influence the development of hypertension (Kranzhofer et al., 1999; 
Damon, 2000; Duerrschmidt et al., 2000; Cheng et al., 2005).   
NE is a neurotransmitter that is released by sympathetic neurons in response to 
various stimuli (e.g., exercise, Fight-or-Flight response).  NE is released in such 
quantities that the amount measured in the plasma accounts for only 10-20% of the total 
NE released from the varicosities.  The remaining 80-90% is either taken up by the 
neurons or the target tissue (usually vascular smooth muscle).  Even though only 10-20% 
of the total NE makes it to the plasma, NE spill-over is usually proportional to SNA 
(Rowell, 1993). 
NE is not usually thought of as being associated with cardiovascular disease; 
however, recent reports have found that elevated sympathetic outflow is associated with 
the development of hypertension and cardiovascular disease (Mancia et al., 1999).  
Zoccali and colleagues (2002), found that plasma NE concentrations as a marker of SNA 
acted as independent predictors of all-cause mortality and cardiovascular morbid events 
in patients with end-stage renal disease.  Although this finding is in a specific population, 
the association of NE concentrations, SNA, and cardiovascular disease is present.  A 
review by Rozanski et al.(1999), explored the psychosocial factors that affect the 
development of cardiovascular disease.  They recognized that in monkeys, chronic 
psychosocial stress was associated with increased cardiovascular disease, and a majority 
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of the documented cases were attributed to increases in SNA.  Excess SNA leading to 
increased NE concentrations has been shown to increase smooth muscle cell proliferation 
via α-adrenoceptor which is a common feature of many cardiovascular diseases including 
atherosclerosis and coronary artery disease (Erami et al., 2002).  
Physical exercise in known to reduce resting SNA in both healthy and mildly 
hypertensive individuals (Meredith et al., 1991).  The reduction in SNA is thought to be 
partly responsible for the lowering of blood pressure that accompanies increased physical 
activity (Collins et al., 2000).  
  NO is one of the most potent vasodilators produced in the vasculature.  NO is 
made by the enzyme nitric oxide synthase (NOS) which has three distinct isoforms: 
endothelial NOS (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS).  NOS 
produces NO by the conversion of L-arginine and oxygen to L-citrulline and NO.  One of 
the main stimuli for the production and release of NO is shear stress acting on the 
endothelium of the vascular wall.  Shear stress is produced as blood flows along the wall 
of the blood vessel.  The physical shear stress is internalized and causes the 
phosphorylation (and activation) of eNOS by many different protein kinases (Boo et al., 
2002; Li et al., 2005).  NO produced in the endothelium diffuses to the vascular smooth 
muscle where it binds and activates soluble guanylyl cyclase.  Guanylyl cyclase causes an 
increase in the intracellular concentration of cyclic GMP which leads to relaxation of the 
muscle (vasodilatation) (Munzel et al., 2003).  In this experiment, NO metabolites 
(NOmet) in the form of nitrates (NO3⎯), and nitrites (NO2⎯) were measured.  In the plasma 
NO can react with hemoglobin to form NO3⎯.  NO can also interact with molecular 
oxygen to form NO2⎯ and with superoxide anion (O2⎯) to form peroxynitrite (ONOO⎯).  
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ONOO⎯ can then break down to either NO3⎯ or NO2⎯ depending on the surrounding 
conditions.  NO also interacts with thiols in the presence of electron acceptors to form 
nitrosothiols which then break down to NO2⎯. NO3⎯ and NO2⎯ are the bi-products of NO 
metabolism and have been found to be a valid indicators of NO production (Kelm, 1999). 
 The effect of exercise (at least in animals), is to increase the activity of NOS 
(Roberts et al., 1999).  In previous bed-rest studies Rudnick et al., (2004) found that the 
amount of eNOS isoform detected in skeletal muscle samples decreased after bed rest 
except for those subjects who had exercise countermeasures during HDBR.  Exercise 
seems to have a protective effect on the expression of eNOS and therefore a protective 
effect on NO production. 
 In addition to being a potent vasodilator NO has the distinction of being anti-
inflammatory, possessing anti-oxidant capabilities, and can prevent cell growth and 
proliferation (Jeremy et al., 1999; Bult et al., 1999; de Gasparo, 2002).  With these 
actions, one would be inclined to assume that increased activation of NOS would be 
beneficial.  On the contrary, excessive activation of NOS can cause NOS to become 
uncoupled, and as a result can lead to the formation of O2⎯ instead of NO.  This molecule 
in excess is harmful to the vasculature because it is a reactive oxygen species (ROS) that 
can directly damage tissue and quench (both enzymatic and non enzymatic) antioxidants 
(Wever et al., 1998).   
 The anti-inflammatory, anti-oxidant, and anti-proliferative functions of NO are all 
cardio-protective (Jeremy et al., 1999; de Gasparo, 2002).  Panza and colleagues (1993) 
found that reduced forearm vasoreactivity in patients with essential hypertension was 
attributable to reduced NO release from the vascular endothelium.  They found that using 
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endothelium dependent vasodilatory mechanisms (acetylcholine) caused a reduction in 
vasodilation compared to normotensive controls, while endothelium independent 
vasodilators (sodium nitroprusside) showed no difference between the groups. 
While not directly vasoactive, the antioxidant capacity of the plasma and the 
molecule asymmetric dimethylarginine (ADMA) can have dramatic effects on the 
availability of NO (Vaziri et al., 1999; Böger, 2003).  Having a decreased antioxidant 
capacity in the plasma is an indicator of one of two things.  Either the production of 
ROS has increased, or the amounts of antioxidants present in the system have decreased.  
If either of these events occurs, there could be a reduction in the availability of NO and 
therefore it is unavailable to elicit its protective functions (Vaziri et al., 1999).  ADMA 
is a structural isomer of L-arginine: it is known to inhibit NOS, and therefore decreases 
the production of NO (Böger et al., 1998; Vallance and Leiper, 2004).  Whatever the 
reason, with less NO, the vasoconstrictive forces of Ang II, ET-1 and NE may begin to 
dominate and hypertension (and cardiovascular disease) may result (Rajagopalan et al., 
1997).  
The delicate balance of vasoconstrictors and vasodilators is crucial in 
maintaining the health of the vascular system.  With either too much vasoconstriction or 
not enough vasodilation this balance is lost and the health of the vasculature is 
compromised. 
1.2.2 Inflammatory Markers 
Inflammation in the body is a natural response to infection or injury.  The role of an 
inflammatory response is to clear infectious agents and repair damaged tissue (Barnes 
and Karin, 1997).  In recent years, the inflammatory process has become a major focus in 
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the progression of many cardiovascular diseases including hypertension, atherosclerosis, 
and strokes (Griendling et al., 2000; Yeh et al., 2001).  Infections leading to 
inflammatory processes in the vasculature are thought to be an initiating factor in many 
cardiovascular diseases (Kalayoglu et al., 2002).  Inflammatory markers are being 
examined to explore the link between inflammation and cardiovascular disease.  The 
inflammatory markers include (but are not limited to) C-reactive protein (CRP) and the 
adhesion molecules E-selectin (E-sel), intracellular adhesion molecule-1 (ICAM), and 
vascular cell adhesion molecule-1 (VCAM) (Hwang et al., 1997; Vallbracht et al., 2002; 
Despres, 2004). 
 CRP is an acute phase protein that is released from the liver in response to tissue 
injury/infection.  CRP release is stimulated by circulating cytokines (de Ferranti and 
Rifai, 2002).  Cytokines are released from damaged cells and act as homing signals for 
the immune cells (Greaves and Gordon, 2005).  The levels of circulating cytokines are 
modulated by the amount (and extent) of damaged tissue and by levels of adipose tissue 
(Mohamed-Ali et al., 1997; Bastard et al., 2000).  CRP is used as a marker of general 
inflammation and has recently become one of the most intriguing molecules as it is being 
considered as an independent risk factor for cardiovascular disease (Ridker et al., 2001).  
Work by Ridker and colleagues (2002) found that the serum levels of CRP were a better 
predictor of first cardiovascular events than LDL serum levels.  Later work by Ridker’s 
group (2005) and also by Nissen and colleagues (2005) found that lowering CRP levels 
actually improved (reversed) plaque formation in patients following an acute coronary 
event.  Based on these findings, using CRP levels as an indication of inflammation may 
be useful in the diagnosis of cardiovascular disease and vascular health. 
 14
 In order for the immune system to function properly, white blood cells 
(monocytes, lymphocytes, etc…) need to be able to leave the blood stream at sites of 
injury/infection.  The precise location where the inflammatory cells are needed is marked 
by an increase in the concentration of cytokines in the area of tissue damage.  In order for 
the immune cells to leave the circulation, some specific events must occur.  
Transmigration (as it is known) is a very complex process and there are a lot of aspects 
that are still being explored, however, there are specific steps that must occur for the 
immune cells to leave the vasculature.  First and foremost there must be a chemical signal 
attracting the cells to the site (Springer, 1994).  This chemical signal also serves to 
activate the endothelial cells lining the lumen of the blood vessel (Zhu et al., 1999).  
When the endothelial cells become activated they begin to produce and express adhesion 
molecules that are vital for migration of immune cells into a tissue.  E-sel, ICAM, and 
VCAM are all adhesion molecules that play roles in the transmigration process (Hwang 
et al., 1997; Zouki et al., 2000).   
The next phase of migration involves rolling adhesions between the vessel wall 
and the immune cells (Lauffenburger and Horwitz, 1996).  Rolling adhesions are 
regulated by the selectin family of molecules of which E-sel plays a major role.  Cells 
continue to roll, until they reach an area of increased integrin expression.  Integrins 
(ICAM and VCAM) create firm adhesions between the cell and the vessel wall and 
facilitate the transmigration process (Price and Loscalzo J, 1999).  
 Adhesion molecules are often sloughed off the endothelium and become dissolved 
in the plasma (Ponthieux et al., 2004).  These soluble versions of the adhesion molecules 
allow for their measurement in the plasma.  With increasing concentrations in the plasma, 
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it can be assumed that there is increased expression and therefore increased inflammation 
(Vallbracht et al., 2002; Galle et al., 2003).  
 Adhesion molecule expression is increased in atherosclerotic lesions (Cybulsky 
and Gimbrone, 1991).  This is thought to be due to endothelial activation by numerous 
factors that are also increased in the atherosclerotic lesion.  Factors like modified LDL, 
ET-1, Ang II, and cytokines are all known to activate endothelial cells and increase 
adhesion molecule expression (Li et al., 1993; Lerman et al., 1995; Scholz et al., 1996; 
Pastore et al., 1999; Funk and Cyrus, 2001).  
 Exercise has been shown to decrease the amount of systemic inflammation (Ford, 
2002).  CRP has also been shown to be affected by the level of physical activity in that 
those with high levels of physical activity generally had lower levels of CRP (Albert et 
al., 2004).  It has also been found that moderate losses in weight due to regular exercise 
result in lower CRP levels (Okita et al., 2004). 
The concentrations of CRP, E-sel, ICAM, and VCAM are being used to 
determine the extent of not only systemic inflammation (Price and Loscalzo, 1999; de 
Ferranti and Rifai, 2002; Ponthieux et al., 2004), but they are also beginning to be used to 
assess vascular health, and the risk of cardiovascular disease (Szmitko et al., 2003a; 
Szmitko et al., 2003b).   
1.3 Previous Bed Rest/Space Flight Studies 
In past bed-rest studies, many of the aforementioned factors have been investigated.  The 
main goals for many of these studies was to assess the role of each of the molecules in the 
maintenance (or lack) of orthostatic tolerance (Buckey, Jr. et al., 1996; Levine et al., 
1997; Bestle et al., 2001).  Due to the nature of the funding for many of the bed rest 
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studies (usually from international space agencies) the majority of past research has 
focused on how the body adapts to microgravity.  A landmark space flight study was the 
1998 Neurolab (STS-90) that was set up to carry out 26 experiments to examine the 
nervous systems response to microgravity.  Of importance to this thesis are a group of 
studies that examined autonomic function, in particular altered vasoconstrictor responses 
(Levine et al., 2002; Ertl et al., 2002). 
1.3.1 Vasoconstrictors 
Many researchers attribute orthostatic intolerance to an impairment of 
vasoconstriction following prolonged microgravity exposure (Convertino and Sather, 
2000; Kimmerly and Shoemaker, 2002).  Many of them attribute this to a blunting of the 
SNA and therefore a reduction in circulating NE following microgravity exposure 
(Fritsch-Yelle et al., 1994; Convertino, 1998).  Reduced NE concentrations cause a 
decrease in the frequency of many of the signaling cascades that result in 
vasoconstriction.  This reduction in use can cause the down regulation of many of the 
protein messengers that are integral to the normal function of the tissue (Bennett et al., 
1994) 
Blunted SNA has been identified as a feature of prolonged bed rest (Shoemaker et 
al., 1998b), however, other bed rest studies have indicated no change or even an increase 
in SNA (Shoemaker et al., 1999; Kamiya et al., 2000a).  The Neurolab experiments that 
examined vasoconstrictor responses to space flight indicated that SNA increased during 
the 16-day mission (Levine et al., 2002).  The responses of other vasoconstrictors are not 
as clear.   
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Haruna et al., (1997) examined the changes to the renin angiotensin system during 
20 days of HDBR.  They found that plasma renin activity and aldosterone were increased 
throughout bed rest, while Ang II levels were only increased in the first few days.  The 
finding of no change in Ang II concentrations is contrary to the findings of Bestle and 
colleagues (2001), who found the Ang II concentrations doubled following 10 days of 
HDBR.  Bestle et al., attributed these changes to a reduced central blood volume and a 
reduction in the distension of the atria.  Convertino et al., (1998) found that Ang II 
infusion before and during 30 days of HDBR caused similar vasoconstriction responses, 
however, during HDBR the Ang II concentration during the infusion was higher than that 
seen before bed rest.   
 ET-1 in HDBR has been less well studied.  Millet et al., (2000) examined ET-1 
concentrations during a 7-day bed-rest study and found that the ET-1 concentrations were 
unchanged following HDBR.  Recent research in our lab revealed elevated ET-1 levels 
following 4 hours of HDBR (Fischer, unpublished 2006) 
1.3.2 Vasodilators 
NOmet have been shown to decrease following 14 days of HDBR in men (Kamiya et al., 
2000b).  Although they did not directly measure NO (or NOmet), the data of Kamiya et al. 
(2000b) is supported by the findings of Shoemaker et al., (1998a) who showed a blunted 
vasodilator response to ischemia following 14 days of HDBR.  While this is not direct 
evidence of reduced NO formation, it does support the idea because of the blunted 
vasodilator response. 
 The antioxidant capacity of the body has been shown to decrease during space 
flight resulting in increased oxidative damage (Smith et al., 2005).  Fewer bed-rest 
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studies have looked at the effects on antioxidant capacity, however, one report has stated 
that the antioxidant capacity is decreased following long term bed rest (Maillet et al., 
2001).  The effect of HDBR on the concentration of ADMA is unknown at this time. 
1.3.3 Inflammatory Markers 
While both bed rest and actual flight studies have been done to assess immune function, 
the majority of these only report on the levels of cytokines, immune cells, and adhesion 
molecule antigens on immune cells and the results are usually from experimental animals 
only (Grove et al., 1995; Schmitt et al., 2000; Sonnenfeld, 2002). 
No study to date has examined the levels of CRP in association with HDBR.  The 
only English studies relating bed rest and CRP levels examined the effect of intra-
articular steroid use versus bed rest in response to rheumatoid arthritis (Sheeran et al., 
1993).  The researchers found that CRP levels were lower in the intra-articular steroid 
group following three and five days of hospitalization, but these results are most likely 
due to the use of intra-articular steroids and can not be attributed to bed rest since there 
was no change in the control group. 
 Like CRP, the levels of circulating adhesion molecules have been studied in a 
limited capacity.  As mentioned, much of the research has revolved around cytokine and 
immune cell changes with either simulated or actual microgravity (Grove et al., 1995). 
1.4 Overview of Current Study 
1.4.1 Purpose 
The purpose of the current study was to examine the effects of 60 days of HDBR on 
markers of vascular health, specifically vasoactive molecules and markers of 
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inflammation, and how countermeasures, in the form of increased protein intake (DIET) 
and resistive and treadmill running exercise (EX), could prevent these changes. 
1.4.2 Hypothesis 
This study was designed to test the hypothesis that 60 days of HDBR would cause 
changes in blood factors associated with increased vasoconstriction and markers of 
inflammation, and that exercise, but not nutrition countermeasures, during the bed rest 
would attenuate the response. 
Specifically: 
1) That 60 days of HDBR will increase the vasoactive molecules Ang II, and 
ET-1 and ADMA, but decrease NE, NOmet, and the antioxidant capacity.  
2) That 60 days HDBR will increase markers of systemic inflammation: CRP 
and the adhesion molecules E-sel, ICAM, and VCAM.  
 3) Exercise is expected to prevent the changes outlined in 1) and 2) while 
DIET is expected to have no effect. 
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2 Methods  
2.1 Subjects 
The recruitment process for this experiment consisted of advertisements–on television, in 
newspapers, magazines, and on the internet–that offered women the opportunity to be 
part of this project.  Twenty six hundred responses were generated and information 
packages were sent to those who inquired.  The information packages consisted of an 
application, a questionnaire on the subject’s way of life, education and professional 
experience, and a medical questionnaire on personal and family medical history.  Three 
hundred and eighty eight of the packages that were sent out were completed and returned.  
Ninety nine individuals were invited for further medical/psychological screenings.  From 
this pool of 99, 24 female subjects ages 25 – 40 were randomly assigned to one of three 
experimental protocols–diet (DIET), exercise (EX), or control (CON)–based on their 
predicted VO2max and primary language spoken.  Specific criteria for inclusion and 
exclusion can be found in appendix A.  Control subjects received no intervention. 
2.2 Experimental Protocols 
The experimental protocol was established at International Working Group (IWG) 
meetings that consisted of the 15 principal investigators and representatives of the space 
agencies that supported the project: the European Space Agency (ESA), the Centre 
National d'Etudes Spatiales (CNES), the National Aeronautics and Space Administration 
(NASA) and the Canadian Space Agency (CSA).  The experiment consisted of two 
campaigns that took place from February 2005 to March 2005, and September 2005 to 
November 2005, at the MEDES space clinic in the Toulouse Rangueil Hospital in 
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Toulouse, France.  Each campaign examined 12 subjects over a 100-day period.  The first 
20 days consisted of baseline data collection (pre-HDBR), where each experimental team 
performed their specific tests on one pair of subjects each day.  The pre-HDBR counted 
down from -20 until the start of head down bed rest (HDBR).  HDBR consisted of the 60 
days of bed rest and counted up from day 1 to 60. During HDBR each of the 
experimental groups performed their specific countermeasure, and strict adherence to a 
recumbent position was ensured by 24h/day monitoring by the MEDES staff.  Following 
the HDBR, 20 days of recovery (post-HDBR) ensued.  During post-HDBR, the 
experimental protocols that were performed in pre-HDBR were repeated. 
2.3 Experimental Countermeasures  
Due to the fact that the experimental countermeasures occurred during HDBR and the 
experimental protocols were done during the pre- and post-HDBR sections, there were 
different energy requirements in each phase.  Nutrition was maintained by the MEDES 
staff according to the plan developed by the IWG as described below. 
2.3.1 Diet Countermeasure (DIET) 
2.3.1.1 Energy intake 
During pre- and post-HDBR periods the energy intake of the subjects was matched to 
their TEE (Total Energy Expenditure) as determined in free living conditions.  Exercise 
level was determined from TEE in free living conditions and RMR (Resting Metabolic 
Rate) as determined by indirect calorimetry.  During HDBR, RMR and fat mass (by 
DEXA) were measured every 15 days.  Caloric intake was corrected accordingly in the 
hopes of maintaining fat mass throughout the study. 
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The CON group received 110% of their RMR.  The EX group received 110% of 
their RMR plus energy related to physical activity. This was accurately calculated and 
administered before each exercise session, maintaining the same energy 
(carbohydrate/fat)-protein relative composition of the entire diet.  The DIET group 
received 110% of their RMR with the same energy (carbohydrate/fat)-protein 
composition throughout the experiment. 
2.3.1.2 Protein Intake 
During pre- and post-HDBR all experimental groups received 1 g of protein/kg/day.  
During HDBR the CON and EX groups maintained this protein intake (1 g/kg/day), 
however, the DIET group received 1.6 g of protein/kg/day to try and prevent the muscle 
wasting caused by the disuse associated with HDBR (Biolo et al., 2005).  Total daily 
energy was achieved by decreasing proportionally the carbohydrate and fat intake in the 
DIET group.  In an attempt to prevent muscle wasting the leucine content in the diet was 
increased from the natural level of 8% to 20% of total amino acid content of the dietary 
protein by increasing the proportion of branched chain amino acids (Stein et al., 1999).  
The increased protein was administered in the form of an added supplement given with 
the main meals. 
2.3.2 Exercise Countermeasure (EX) 
During the exercise sessions the subjects were monitored and supervised at all times.  
Each subject participated in two (more if necessary) orientation sessions to familiarize 
themselves with the equipment and all training and testing procedures. 
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2.3.2.1 Cardiovascular Training Program and LBNP 
The EX group performed a daily regimen of 35 min of treadmill running at 1-1.2 times 
body weight followed by 10 min of static LBNP 3-4 times per week.  This protocol was 
similar to that of Cao et al., (2005) with the exception of 10 minutes of static LBNP 
instead of 5 minutes, and the protocol was performed 3-4 times/week, instead of 6 
times/week.   Subjects performed an interval exercise protocol (40–80% peak oxygen 
consumption) with both warm-up and cool-down sessions that consisted of walking at a 
comfortable pace. 
 
   Figure 2.1 Schematic of the LBNP Treadmill 
   (From Smith et al., 2003) 
2.3.2.2 Resistance Training Protocol   
Each subject in the exercise group performed warm-up and cool-down periods consisting 
of 10-15 minutes of stationary cycling at low resistance and slow speed, as well as 
stretching of the muscle groups involved in the resistance training. 
Resistance training of the knee extensor and plantar flexor muscle groups was 
conducted on a flywheel ergometer that had been modified for bed rest.  This is similar to 
the equipment described by Tesch et al., (2005).  The subjects trained both legs using 
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concentric and eccentric muscle actions; both actions together were considered one 
repetition.  Each session consists of a series of warm-ups followed by the main exercise 
that included four sets of seven repetitions performed with maximal effort.  Force and 
angle-specific force in each repetition were measured and simultaneously shown on a 
computer display for instant feedback. 
2.4 Ethics 
2.4.1 Ethics Committee  
Before any experimental protocol began the coordinating investigator submitted the 
protocol, information form, and consent-of-participants document to the Comités 
Consultatifs de Protection des Personnes dans la Recherche Biomédicale (CCPPRB). 
 Once the CCPPRB approved the protocol, a written copy of the approval was 
forwarded to the "Agence Française de Sécurité Sanitaire des Produits de Santé" 
(AFSSAPS) for the declaration of intent.  No experimental protocol could commence 
without written consent of the CCPPRB, acknowledgement of receipt of the declaration 
of intent by the AFSSAPS, and a signature from each contractual party involved. 
2.4.2 Study Conduct 
The study was performed in accordance with the ethical principles stated in the 
Declaration of Helsinki 1964, and all applicable amendments. 
2.4.3 Information of Participants 
The coordinating investigator, or a physician designated by him/her, collected consent 
from each participant.  Prior to this the investigator or the physician informed each 
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participant of the objectives, benefits, risks, and requirements imposed by the study, and 
its specific details. The investigator or the physician also provided the participant with an 
information sheet in clear, simple language. A copy of the information sheet was given in 
the "Information for and consent of participants" document attached to the protocol.  The 
study participant was allowed ample time to inquire about details of the study and to 
decide whether or not to participate in the study. 
2.4.4 Informed Consent 
Each participant gave written informed consent personally before entering the study.  
Two copies of the consent form were completed, signed and dated by the participant and 
the physician who conducted the informed consent.  The physician gave one copy of the 
consent form to the participant and retained the other copy. 
A copy of the consent form meeting the requirements of the Good Clinical Practice 
recommendations of the International Conference on Harmonisation (ICH) was given in 
the "Information for and consent of participants" document attached to the protocol. 
2.5 Blood Collection and Separation 
Blood samples were drawn by the MEDES staff between 7:00 and 7:30 am on days pre-
HDBR-06 (six days before bed rest) and HDBR60 (on the last day of bed rest).  Subjects 
were in a fasted state prior to blood collection.  14 ml of blood was collected and 
separated into 4, 6, 2.5 and 1.5 ml draws termed Angiotensin II (Ang II), Main, Serum 
and Catecholamine (CATS) respectively, each designed for the isolation of different 
blood factors.   
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2.5.1 Ang II draw 
160 µL of EDTA and 80 µL of Bestatin were added to the 4 ml aliquot tube to isolate 
Angiotensin II.  The sample was centrifuged at 2500 RPM at 4ºC for 10 min to separate 
the cell portion from the plasma.  2000 µL of plasma was isolated and stored at minus 
80ºC until analysis. 
2.5.2 Main draw 
240 µL of EDTA was added to the 6 ml draw.  The sample was centrifuged at 2500 RPM 
at 4ºC for 10 minutes to separate the cell portion from the plasma.  The plasma was 
divided into aliquots of 1000 µL for Endothelin-1 (Endo-1), 200 µL for Nitric Oxide 
metabolites (NOmet), 100 µL for asymmetric dimethylarginine (ADMA), and 50 µL for 
each of: soluble intracellular adhesion molecule-1 (ICAM), soluble vascular cell adhesion 
molecule-1 (VCAM), and total antioxidant capacity (ANTIOX).  With the plasma 
separated, the red blood cell (RBC) pellet was re-suspended with a 0.9% Sodium 
Chloride Injection, USP supplied by B׀Braun (Center Valley, PA catalogue  number 
7983-03), and then prepared according to the method of Bøyum (Bøyum, 1964; Bøyum, 
1968) for the isolation and separation of lymphocytes.  The remaining RBC pellet was 
washed three times with 0.9% Sodium Chloride Injection, USP once more, and a sample 
of RBC was frozen for future analysis.  All samples were stored at minus 80ºC until 
analysis.  Excess plasma was saved and stored in the same manner. 
2.5.3 Serum draw 
Hematocrit was taken in triplicate from the 1.5 ml blood sample before it was allowed to 
clot at room temperature.  The clot was loosened from the edge of the test tube with a 
wooden dowel and was then centrifuged at 2500 RPM at 4ºC for 10 min to separate the 
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cell portion from the serum.  The serum was drawn off and separated into aliquots of 50 
µL for each of C-reactive protein (CRP) and E-selectin (E-sel).  The samples were stored 
at minus 80ºC until analysis.  Excess serum was saved and stored in the same manner. 
2.5.4 CATS draw 
62.5 µL of EGTA/Glutathione was added to the 1.5 ml aliquot tube to isolate 
Norepinephrine (NE).  The sample was centrifuged at 2500 RPM at 4ºC for 10 min to 
separate the cell portion from the plasma.  Approximately 1250 µL of plasma was 
isolated and stored at minus 80ºC until analysis. 
2.6 Blood Analysis 
All of the blood analysis was performed in the Kinesiology Biochemistry lab (BMH 
2401) at the University of Waterloo.  An outline of the specific procedures can be found 
in appendix C.  Quantification of the blood factors was performed using Enzyme-Linked 
Immunosorbent Assay (ELISA), Enzyme Immunoassay (EIA) Radioimmunoassay (RIA), 
spectrophotometry, and high performance liquid chromatography (HPLC).   
  Ang II was analyzed using an EIA purchased from SPI bio (Montigny le 
Bretonneux, France catalogue number – A05880).   
  ET-1 was analyzed using an EIA supplied by R&D Systems (Minneapolis, MN, 
USA catalogue number – BBE 5).  Plasma NOmet were quantified using a nitric oxide 
analyzer (model 280i with software version 3.2, according to the procedures detailed in 
the manufacturers operating manual, Sievers Instruments, Inc., Boulder CO, USA).  
ADMA concentrations were assessed using an ELISA from ALPCO Diagnostics 
(Windham, NH, USA catalogue number – 017-EA201/96).  ICAM was measured in the 
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plasma using an EIA purchased from R&D Systems (Minneapolis, MN, USA catalogue 
number – BBE 1B).  The measurement of VCAM was done with an EIA from R&D 
Systems (Minneapolis, MN, USA catalogue number – DVC00).  ANTIOX was measured 
using an ELISA purchased from ALPCO Diagnostics (Windham, NH, USA catalogue 
number – 30-5200). 
  CRP was quantified using an ELISA purchased from ALPCO Diagnostics 
(Whindham, NH, USA catalogue number – 030-9710s).  E-sel concentrations were 
determined using and EIA from R&D Systems (Minneapolis, MN, USA catalogue 
number – BBE 2B).  All of the instructions from the purchased assay kits were followed 
without deviation.   
  NE was quantified using HPLC from Waters Alliance using an HPLC 2690 
(Milford, MA, USA).  Samples were prepared following procedure in appendix C, and 
analyzed at a flow rate of 1.2 ml/min using a 15 cm C18, 5 µm particle size Supelco 
Supelcosil (Sigma-Aldrich Corporation, Bellefonte, PA, USA catalogue number –  
58230U) and Waters Guard column module with Resolve C18 guard inserts (Milford, 
MA, USA catalogue number –  WAT085824). 
2.7 Plasma Volume 
Plasma volume (PV) was assessed using a carbon monoxide (CO) re-breathing system as 
described by Burge and Skinner (1995).  Subjects lay supine and were required to breathe 
through both an open and closed loop system; both systems were supplemented with 
100% oxygen.  The test started with 5 minutes of breathing from the open loop in order to 
flush nitrogen stores from the body (Burge and Skinner, 1995).  Following the 5 minutes, 
the subject gave a signal indicating the end of a normal expiration.  Upon this signal, the 
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subject was turned into the closed loop system via a three-way valve.  Normal breathing 
was maintained for an additional 5 minutes to ensure that the subject was comfortable 
with the increased resistance of the closed loop, and was able to maintain normal resting 
tidal volume.  The flow of oxygen to the closed loop was matched to the subject’s 
metabolic demands by adding oxygen to a 5 L bag attached to the closed loop.  The flow 
into the bag was maintained so as to not over- or under-inflate the bag.  Following this 
period, a 3ml venous blood sample was drawn by a member of the MEDES staff into a 
dry heparanized syringe (Vital Signs Inc., NJ, USA).  Venous blood was assessed (Nova 
CO-oximeter, Nova Biomedical, Mississauga, ON, Canada) to determine the %CO on the 
hemoglobin in the sample.  Subjects were then given a priming dose of between 20 and 
28 ml of 100% CO in order to raise the %CO bound to the hemoglobin to approximately 
3-5%.  Subjects continued to breathe in the closed system for 10 minutes after which time 
another venous blood sample was collected to measure the result of the priming dose.  
Upon the results of the priming dose, a test dose was administered to cause a change in 
the %CO bound by approximately 6.5%.  This was done with a bolus injection of 
between 50 and 60 ml 100% CO.  Following another 10 minute interval, the %CO bound 
was again measured by a venous blood sample, and the test %CO bound was assessed.  
The test dose typically gave a %CO bound of between 8% and 14%.   
 The line and stopcock used to administer the CO was flushed three times to 
ensure minimal contamination with room air.  The subjects were continually reminded to 
keep a tight seal on the mouthpiece, but in the event of any feelings of light headedness  
they could come off the mouthpiece at any time.  Calculations of blood volume, plasma 
volume and of red cell volume were calculated as per Burge and Skinner (1995).  
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2.8 Statistics 
All data are presented as mean ± SD and percent change. Statistical analyses were 
performed using the Statistical Analysis Software program (SAS Institute, Cary NC, 
USA).  Effects of diet, exercise, and a control group on the physiological and 
biochemical dependent measures before and after 60 days of HDBR were compared 
using a two-way repeated measures ANOVA with least squares difference post hoc 
analysis if required. A p < 0.05 was accepted as statistically significant.  The interaction 
of HDBR and Group was also investigated in the ANOVA to determine the interaction 
between the two independent variables.  Again, p < 0.05 was accepted as significant. 
  Correlations between ∆ Ang II and ∆ PV were analyzed using Sigma Stat for 
Windows v3.0 (SPSS Inc., Chicago, IL, USA).  Significance was accepted as p < 0.05.  
SAS was also used to assess power calculations for CRP.  This analysis was used to 
assess the number of subjects that would be required per group in order to achieve 
significance.   
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3 Results  
This study explored the relationship between 60 days of HDBR, and factors linked with 
cardiovascular disease.  The subject’s characteristics can be found in Table 3.1. 
3.1 Weight and Plasma Volume 
All 24 of the women completed the 60 days of HDBR, and all of the subjects lost on 
average 3 kg of body mass.  The CON group lost the most weight with a 3.2 kg decrease 
(p < 0.0001), followed by the EX group with a loss of 3.0 kg (p < 0.0001), and finally the 
DIET group lost an average of 2.7 kg (p < 0.0001) (Figure 3.1).  Absolute values of 
plasma volume were reduced following 60 days of HDBR, but the reduction varied 
between groups.  The EX group had a decrease of 98.4 ml (3.4% decrease, n = 7, p = 
0.4), the CON group had a decrease of 209.8 ml (7.8% decrease, n = 8, p = 0.058), and 
the DIET group had the largest decrease of 415.4 ml (13.9% decrease, n = 8, p = 0.0007) 
(Figure 3.2).  When plasma volume was normalized by weight (ml/kg) there was no 
difference from pre- to post-HDBR (Figure 3.3).   


























A1 Exercise Czech 28 65.4 170    
B1 Exercise Dutch 36 55.4 158    
C1 Exercise French 35 56.9 172    
D1 Exercise English 27 51.5 152    
E2 Exercise French 36 58.6 163    
F2 Exercise English 35 62 168    
G2 Exercise French 33 52.3 164    
H2 Exercise French 31 70.4 171 33 ± 3.6 59.1 ± 6.5 165 ± 7.0 
E1 Control Finish 29 57.4 163    
F1 Control Polish 31 57.8 172    
G1 Control French 32 58.7 170    
H1 Control French 40 56 158    
A2 Control French 38 61.2 166    
B2 Control French 34 55.3 161    
C2 Control French 34 53.6 157    
D2 Control French 37 49.3 155 34 ± 3.7  56.2 ± 3.6 163 ± 6.2 
I1 Diet French 29 65.8 168    
J1 Diet French 36 57.5 166    
K1 Diet German 29 63.3 165    
L1 Diet Polish 25 60.8 174    
I2 Diet Finish 31 61.6 172    
J2 Diet Finish 29 54.2 166    
K2 Diet Finish 31 69.9 181    
L2 Diet Swiss 25 60.9 170 29 ± 3.5 61.8 ± 4.8 170 ± 5.4 
All 
Subjects      32 ± 4.1 59.0 ± 5.4 166 ± 6.8 
Averaged data are mean ± SD 
Alpha-numeric code refers to subject (A-L) and campaign (1 or 2) 



































Figure 3.1 The effect of 60 days of HDBR on weight (kg) 














































Figure 3.2 The effect of 60 days of HDBR on plasma volume (ml) 


























Figure 3.3 The effect of 60 days of HDBR on normalized plasma volume 
(ml/kg) 
















































p = 0.0007p = 0.008
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3.2 Baseline Differences 
Many of the comparisons made in this thesis were within group comparisons, however, it 
must be stated that in a few of the measured variables there were significant differences 
seen in baseline values between the groups.  The subjects were randomized according to 
their predicted VO2max and primary language spoken.  While we made every attempt to 
randomize the subjects, uneven distribution of other variables is unavoidable.  A 




Table 3.2 Baseline Values for Measured Blood Variables 
Group 
Parameter Exercise Control Nutrition 
Ang II (pg/ml) 21.5 ± 11.8 19.2 ± 11.9 14.8 ± 8.4 
ET-1 (pg/ml) 0.59 ± 0.088 0.63 ± 0.14 0.65 ± 0.076 
NE (pg/ml) 256.6 ± 132.3 229.1 ± 100.3 271.1 ± 133.8 
NOmet (µmol/l) 62.5 ± 30.2* 32.1 ± 11.0 41.8 ± 16.9 
ANTIOX (µmol/l) 271.7 ± 49.6 268.4 ± 38.6 289.2 ± 21.6 
ADMA (µmol/l) 0.68 ± 0.13* 0.92 ± 0.084 0.83 ± 0.17 
CRP (µg/ml) 0.251 ± 0.212 0.279 ± 0.202 0.157 ± 0.142 
E-sel (ng/ml) 17.4 ± 5.1* 25.7 ± 10.9 25.5 ± 7.8 
ICAM (ng/ml) 178.9 ± 35.4 164.7 ± 45.1 178.3 ± 35.4 
VCAM (ng/ml) 553.1 ± 101.4 624.3 ± 85.8* 533.0 ± 112.2 
Values are mean ± SD 
* Indicates baseline values are significantly different from other groups (p < 0.05) 
ANG II = angiotensin II, ET-1 = Endothelin-1, NOmet = nitric oxide metabolites, 
ANTIOX = total antioxidant capacity, ADMA = asymmetric dimethylargenine 
CRP = C-reactive protein, E-Sel = E-selectin, ICAM = soluble intracellular 




3.3 Vasoactive Molecules  
Table 3.3 contains the values of the measured vasoactive molecules.  The values are 
mean ± SD. 
 The most drastic change seen in any of the molecules measured occurred with the 
molecule Ang II.  This molecule showed an increase in the CON and DIET groups of 
52.9% (p = 0.014) and 124.2% (p < 0.0001) respectively, with no change seen in the EX 
group (p = 0.80) (Figure 3.3).  ET-1 showed no changes in any of the groups (Figure 3.4).  
NE showed decreases in all groups, however, these decreases were not significant (Figure 
3.5).  Relationships between ∆ Ang II and ∆ PV did not show strong correlations in any 
of the experimental groups.  In the EX group r = -0.081 (p = 0.849), in the CON group r 
= -0.188 (p = 0.780), and in the DIET group r = 0.422 (p = 0.298). 
 NOmet in the plasma showed decreases in all groups.  The EX group decreased 
37.7% (p = 0.013), the DIET group decreased by 42.1% (p = 0.056), and the CON group 
decreased by 17.3%, although this was not significant (p = 0.53) (Figure 3.6).   
 The antioxidant capacity of the plasma showed a trend towards a decrease in all 
groups, however, these changes were not significant (Figure 3.7).  The concentrations of 



















Table 3.3 The Effect of 60 Days HDBR on the Concentration of Plasma Vasoactive Molecules 
 Group 
Variable Exercise Control Diet 
 Pre HDBR Post HDBR Pre HDBR Post HDBR Pre HDBR Post HDBR 
ANG II (pg/ml)  21.5 ± 11.8 20.6 ± 19.3 19.2 ± 11.9 29.3 ± 12.3* 14.8 ± 8.4 33.2 ± 17.8* 
ET-1 (pg/ml) 0.59 ± 0.088 0.63 ± 0.10 0.63 ± 0.14 0.62 ± 0.093 0.65 ± 0.076 0.60 ± 0.090 
NE (pg/ml) 256.6 ± 132.3 227.8 ± 83.7 229.1 ± 100.3 188.0 ± 79.8 271.1 ± 133.8 201.9 ± 118.2 
NOmet (µmol/l)  62.5 ± 30.2 38.9 ± 17.6* 32.1 ± 11.0 26.5 ± 14.4 41.8 ± 16.9 24.2 ± 10.04* 
ANTIOX (µmol/l) 271.7 ± 49.6 244.7 ± 33.8 268.4 ± 38.6 247.9 ± 26.2 289.2 ± 21.6 278.5 ± 20.3 
ADMA (µmol/l) 0.68 ± 0.13 0.76 ± 0.11 0.92 ± 0.084 0.87 ± 0.14 0.83 ± 0.17 0.83 ± 0.22 
Values are means ± SD 
* Indicates significance of p < 0.05 for pre to post comparison. 
ANG II = angiotensin II, ET-1 = Endothelin-1, NOmet = nitric oxide metabolites, ANTIOX = total antioxidant capacity, 


































 Figure 3.4 The effect of 60 days HDBR on the concentration of 
angiotensin II (pg/ml) 






























































Figure 3.5 The effect of 60 days HDBR on the concentration of 
endothelin-1 (ng/ml) 








































































 Figure 3.6 The effect of 60 days HDBR on the concentration of 
norepinephrine (pg/ml) 











































































Figure 3.7 The effect of 60 days of HDBR on the concentration of 
nitric oxide metabolites (µmol/l) 










































































Figure 3.8 The effect of 60 days of HDBR on the antioxidant 
capacity of the plasma (µmol/l) 



























































Figure 3.9 The effects of 60 days HDBR on the concentration of 
asymmetric dimethylarginine (µmol/l) 

























HDBR day 60p < 0.0001
p = 0.003
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3.4 Inflammatory Markers  
Table 3.4 contains the values of the measured inflammatory markers.  The values are 
mean ± SD. 
 There was a non-significant decrease in the serum concentration of CRP in the 
EX group dropping by 56.3% (p = 0.12).  The CON group showed an increase of 60.1% 
(p = 0.063), and the DIET group increased by 47.6% (p = 0.40).  The directions of the 
changes in the EX group (increasing), and the CON and DIET groups (decreasing), 
resulted in a significant HDBR x Group interaction effect (p = 0.05) (Figure 3.10).   
 Power analysis on CRP showed that the numbers required to achieve significance 
were well beyond those that were in this experiment.  The EX group would have needed 
19 subjects, the CON group would have needed 39 subjects, and the DIET group would 
have needed 48 subjects to achieve a power of 0.85 based on the group means and 
standard deviation of the differences of the mean. 
 ICAM showed no significant changes in any of the groups (Figure 3.11), while E-
sel and VCAM showed significant changes.  However, these changes occurred in 
different groups.  E-sel showed an increase of 18.2% (p = 0.003) in the DIET group, and 
VCAM showed an 8.0% increase (p = 0.016) in the CON group, and a non-significant 
6.5% increase (p = 0.08) in the DIET group.  The EX group showed no changes in either 














Table 3.4 The Effect of 60 Days of HDBR on Markers of Systemic Inflammation   
 Group 
Variable Exercise Control Diet 
 Pre HDBR Post HDBR Pre HDBR Post HDBR Pre HDBR Post HDBR 
CRP (µg/ml) 0.251 ± 0.212 0.110 ± 0.154 0.279 ± 0.202 0.448 ± 0.416 0.157 ± 0.142 0.232 ± 0.185 
E-SEL (ng/ml) 17.4 ± 5.1 16.9 ± 5.2 25.7 ± 10.9 25.1 ± 9.6 25.5 ± 7.8 30.1 ± 9.5* 
ICAM (ng/ml) 178.9 ± 35.4 181.9 ± 25.2 164.7 ± 45.1 166.3 ± 50.8 178.3 ± 35.4 187.7 ± 33.7 
VCAM (ng/ml) 553.1 ± 101.4 574.7 ± 88.3 624.3 ± 85.8 674.0 ± 98.2* 533.0 ± 112.2 567.8 ± 119.4 
Values are means ± SD 
*  Indicates significance of p < 0.05 for pre to post comparison. 





































Figure 3.10 The effect of 60 days of HDBR on the concentration of 
C- reactive protein (ng/ml) 









































































Figure 3.11 The effect of HDBR on the concentration of the different 
adhesion molecules (ng/ml) 
Values are mean ± SD 
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4 Discussion  
This study was the first long-term bed-rest study that examined the physiological changes 
that occurred in women.  While studies have been done that compare the responses of 
men and women, they have been relatively short in duration (14 – 17 days) (Convertino 
et al., 1977; Convertino, 1998).   
With respect to the hypotheses outlined: 
1)  Following 60 days of HDBR, Ang II increased as hypothesized.  HDBR 
had no effect on the concentrations of ET-1 or ADMA.   
NE and the antioxidant capacity showed non significant decreases in all groups 
and NOmet showed significant decreases in the EX and DIET groups.  
2) Many of the markers of vascular inflammation that were hypothesized to 
increase following 60 days of HDBR were significantly elevated when compared to 
baseline values.  CRP showed non significant changes in all groups, however the 
directions of the changes (decrease in the EX while increasing in the CON and DIET 
groups) led to a significant HDBR by Group interaction.  E-sel showed a significant 
increase in the DIET group but not in the CON and EX groups, while ICAM showed no 
significant change in any group.  VCAM showed a significant increase in the CON 
group, and a non-significant increase in the DIET group, with no change in the EX group. 
  3) As outlined in 1) and 2) exercise was able to attenuate changes that 
occurred with the exception of NOmet, while DIET (for the most part) was ineffective at 
preventing any changes. 
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The results of this experiment indicate that 60 days of HDBR can cause shifts in 
the blood borne markers that collectively indicate changes in vasoconstrictor and 
inflammatory responses suggesting an environment of reduced vascular health. 
4.1 Vasoactivity  
The delicate balance between vasoconstrictors and vasodilators is one of the main 
determinants of vascular tone.  If the balance is tipped in favor of one side over the other, 
vascular tone can be altered and the health of the vasculature can be compromised. 
4.1.1 Angiotensin II 
One of the main findings of this study is the large increase in Ang II in the CON and 
DIET groups, with no change seen in the EX group.  This finding is supported by Bestle 
et al., (2001) who found a doubling of Ang II following 10 days of HDBR.  The Bestle 
paper attributed the increase to central hypovolemia causing reduced pressure on the atria 
of the heart; this mechanism does not explain the sustained increase following such a 
long period of time.  Since the main function of Ang II is to maintain fluid balance via 
aldosterone release and increased re-absorption of sodium in the kidney, Bestle’s 
explanation may be relevant in short term maintenance of plasma volume.  Following 60 
days of HDBR, the increase seen in the concentration of Ang II in the CON and DIET 
groups may have been an attempt to return plasma volume back to normal levels.  This is 
because of the sustained reduction in plasma volume that was observed in the CON and 
DIET groups.  The EX group showed no reduction in plasma volume, and therefore there 
was no reason for Ang II to be increased in that group.  
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 An interesting feature of Ang II that needs to be mentioned is its role in 
inflammation.  Increasing evidence is linking Ang II to many processes in the 
inflammatory pathway, including increased permeability, leukocyte infiltration, and 
tissue remodeling (Cheng et al., 2005).  While increasing the permeability of the 
vasculature can have its disadvantages, it is the increased leukocyte infiltration and tissue 
remodeling that are critically important in vascular health.   
Ang II can stimulate the production of adhesion molecules (both selectins and 
integrins (ICAM and VCAM)) through redox sensitive pathways.  Ang II increases the 
production of ROS and this leads to the expression of nuclear factor kappa B (NF-κB) 
and other redox sensitive messengers (Suzuki et al., 2003; Nakashima et al., 2006).  NF-
κB is a transcription factor that is necessary for the production of many immune 
molecules including the aforementioned adhesion molecules as well as cytokines and 
other factors that activate various cell types (endothelial cells, vascular smooth muscle) 
(Suzuki et al., 2003).  Since we saw increases in Ang II in the same groups that showed 
increases in the adhesion molecules the increases in the adhesion molecules may have 
been in response to the increased Ang II concentrations. 
4.1.2 Nitric Oxide Metabolites 
The decrease in NOmet seen in all groups is contrary to what was hypothesized.  We 
expected to see a decrease in the CON and DIET groups, but expected exercise to 
preserve plasma concentrations of NOmet.  The decrease in NOmet has been seen in 
previous bed rest studies by Kamiya et al., (2000b) who gave two explanations for the 
decrease in NOmet. Firstly, the lack of physical exercise may reduce NO expression.  The 
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reasoning for this explanation is due to the fact that an increase in physical activity is 
known to increase NO production through phosphorylation (activation) of eNOS (Sessa 
et al., 1994; Roberts et al., 1999), so a reduction in physical activity may reduce NO 
production because of less eNOS activation.  Secondly, they proposed that hypovolemia 
may have reduced the shear stress in the blood vessels, therefore reducing the formation 
of NO.  NO production is stimulated by shear sensitive mechanisms, and a reduction in 
these mechanisms may reduce NO production.  The decrease seen in the EX group was 
surprising, and does not fit with the explanations given by Kamiya et al. (2000b).   
The changes seen in the concentration of NOmet can not be attributed to changes in 
the antioxidant capacity or the concentration of ADMA.  Since there were no significant 
changes in either factor it can be assumed that neither affected the production of NOmet.  
The data given for Ang II and NOmet support the idea that 60 days of HDBR 
causes changes in the balance between vasoconstrictors and vasodilators that can change 
the normal functioning conditions of the vasculature.  
4.2 Inflammation 
Inflammation is a normal and expected part of the healing process.  While it is welcomed 
in most circumstances, other times it can have dramatic and negative impacts on an 
individual’s health (Stokes et al., 2002; Galle et al., 2003).  More and more 
cardiovascular diseases have been linked to inflammatory processes, and a growing 
number of researchers are looking at the link between inflammation and exercise as a 
way to manage disease (Ford, 2002; Nicklas et al., 2004).   
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 While exercise is known to have beneficial effects on markers of systemic 
inflammation, the effects of HDBR on these same markers had not been explored prior to 
this study.  Experiments by Laufs and colleagues (2005) showed that in rats, inactivity 
caused endothelial dysfunction, increased oxidative stress, reduced eNOS activity, and 
increased atherosclerotic plaque formation.  The disease atherosclerosis is now 
considered to be, in part, an inflammatory disease.  Elevated levels of CRP are associated 
with the development of atherosclerosis, and in an atherosclerotic lesion, endothelial cells 
are activated, increasing the expression of adhesion molecules and cytokines (Libby et 
al., 2002; Blankenberg et al., 2003). 
4.2.1 C-reactive Protein 
While CRP has been linked to many disorders that are associated with inactivity (Ridker 
et al., 2001), this is the first report on the effect of long term bed rest on the levels of 
CRP.  With the significant HDBR and Group interaction the directions of change for all 
of the experimental groups becomes very meaningful.  An apparent increase in the 
concentration of CRP in the CON and DIET groups following HDBR indicates that the 
amount of systemic inflammation may have increased.  This has increased meaning when 
you consider that the EX group showed a tendency to decrease the concentration of CRP, 
indicating that the amount of systemic inflammation seemed to have decreased in this 
group.  Previous research into the link between exercise and CRP levels confirms that 
exercise is able to reduce levels of CRP (Okita et al., 2004; Obisesan et al., 2004; Albert 
et al., 2004).  When the magnitudes of the changes seen in CRP are examined in relation 
to the clinical values that are becoming indicative of cardiovascular disorders, the values 
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seen here fall within the lowest quintile of risk (≤ 0.49 µg/ml).  While this does not 
indicate increased risk for the development of cardiovascular disease, the changes can be 
associated with the amount of inflammation in general (Ridker et al., 2002).   
While reduced CRP levels are associated with weight reductions (Okita et al., 
2004), it has also been found that the amount of adipose tissue may play a role in 
modulating cytokine levels, which influence the release of CRP (Mohamed-Ali et al., 
1997; Bastard et al., 2000).  The EX group maintained their thigh and most of their calf 
volume, while the CON and DIET groups lost 21 ± 1% and 24 ± 2% volume in the thigh 
respectively (p < 0.05 for both) (Burd et al., 2006).  It can be assumed that the majority of 
this volume is due to maintenance of muscle mass.  With the CON and DIET groups 
losing such a large amount of muscle mass, the proportion of adipose tissue relative to 
lean mass increased.  This increased ratio may lead to higher production of cytokines that 
can stimulate the release of CRP.  With the maintenance of leg volume in the EX group, 
the lean mass to adipose ratio would be maintained and the increased CRP would not 
occur.  Also the exercise itself is thought to have a positive effect on CRP levels 
(Despres, 2004; Okita et al., 2004).  
Another reason for the increase seen in the levels of CRP in the groups that did 
not perform any exercise could be due to the increased Ang II levels in the same groups.  
As mentioned earlier, Ang II is emerging as a major mediator of inflammation.  Increased 
Ang II levels have been associated with increased vascular smooth muscle cell activation 
and increased cytokine production (Kranzhofer et al., 1999; Cheng et al., 2005).  These 




Due to the variable nature of CRP and the wide range of physiologic 
concentrations that can be achieved, power analysis reveals that the group sizes were too 
small to achieve significance.  Thus, if the changes were to be seen in CRP, larger groups 
were needed (see section 4.3 Limitations). 
4.2.2 Adhesion Molecules 
The increases seen in the DIET and CON groups for the adhesion molecules E-sel and 
VCAM respectively, indicate that there may have been an increase in the amount of 
inflammation (Hwang et al., 1997; Libby and Ridker, 1999).  In spite of the fact that the 
increases seen occurred in different groups (DIET for E-sel, and CON for VCAM), the 
fact that VCAM approached significance in the DIET group, and that there was no 
increase seen in the EX group, helped to support the idea that HDBR may increase 
systemic inflammation and exercise can protect against it (Ford, 2002; Despres, 2004).   
4.3 Limitations 
The large number of research groups involved in this study meant that some groups were 
unable to measure some variables in the manner that they wanted.  For example, with so 
many groups involved, the quantity of blood that was available for each group, and the 
time available with the subjects was severely limited.  This meant that the project was 
limited to 14 ml of blood taken on one day before bed rest and one day during bed rest.  
The original proposal was to take the same samples on consecutive days in order to get a 
more accurate average.  This was not possible, because with so many groups requesting 




 Another limitation of the study is the fact that blood samples were only taken 
before (pre-HDBR-06) and at the end of bed rest (HDBR60).  This two point comparison 
prevented us from observing the timeline of the changes.  Ideally, it would have been 
beneficial to collect samples from the subjects during the bed rest so that a profile of how 
each molecule changed could be established.  This would have given us the chance to see 
if any of the changes were in the process of either increasing or decreasing in magnitude 
at the end of the bed rest, or if the molecules that showed no change had in fact done so 
and had returned back to baseline values for the final sample. 
 When looking at CRP levels, according to the power analysis preformed, the EX, 
CON, and DIET groups, would have needed 19, 39, and 48 subjects respectively to 
achieve significance.  These large numbers reflect the variable nature of this molecule 
and were unattainable in this experiment. 
 With respect to variables measured, it would have been beneficial to measure 
more markers of both fluid regulation and inflammation.  The measurement of plasma 
renin activity (or perhaps aldosterone) would have given a better indication of why Ang 
II was increased: for fluid regulation or for other reasons.  Similarly, measuring other 
markers of inflammation, specifically pro- or anti-inflammatory cytokines, would give a 
better indication of the inflammatory state of the body.   
4.4 Conclusion and Summary 
Sixty days of HDBR in women caused a shift in many cardiovascular risk factors towards 
a state of increased risk.  These changes include a propensity for increased vasomotor 
tone, as a result of a higher concentration of Ang II, and a decreased concentration of 
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NOmet.  Exercise during the bed rest prevented the increase in Ang II, but had no 
protective effect on the NOmet.  Increased protein intake by the DIET group did not have 
any important effects on vasoactive molecules compared to the CON group.   
 Sixty days of HDBR also increased the release of CRP and adhesion molecules 
expression in the non-exercising subjects.  Increased protein intake had no effect on these 
values.  Exercise seemed to protect the body from increased inflammation during 
prolonged bed rest. 





Specific Inclusion and Exclusion Criteria of the Subjects 
Acceptance criteria 
- Healthy female volunteer (see below the description of medical tests and laboratory analysis), 
- Age 25 to 40, 
- Non smokers, 
- No alcohol, no drug dependence and no medical treatment, 
- Height less than 185 cm, 
- No overweight nor excessive thinness with BMI (weight Kg/ height m2) between 20 and 25, 
- Regular menstrual cycles, 
- No personal nor family past record of chronic or acute disease or psychological disturbances 
which could affect the physiological data and/or create a risk for the subject during the 
experiment, 
- Active and free from any orthopedic, musculoskeletal and cardiovascular disorders, 
- Subject who accepts to vaccinated against flu during the autumn preceding the 
hospitalization, 
- Subjects must be volunteer for psychological investigations, 
- Subject to be covered by a Social Security system, 
- Free of any engagement during four consecutive months.  
 
Specific exclusion criteria  
- Having given blood (more than 300ml) in a period of three months or less before the start of 
the experiment, 
- Subject already participating in a clinical research experimentation  
- Subject who is in the exclusion period in the Healthy Volunteers National Register of the 
French Ministry of the Health 
- Poor tolerance to blood sampling, 
- Past record of orthostatic intolerance, 
- History of hiatus hernia or gastroesophageal reflux, 
- Cardiac rhythm disorders, 
- History of inguinal hernia, 
- History of vestibular disease, 
- History of central or peripheral nervous system disease, 
- History of active claustrophobia, 
- History of severe hypersensitivity, 
- Known or suspected pregnancy, 
- Status post-partum or post-abortion within a period of 3 months prior to the start of the study, 
- Breastfeeding or within 2 months after stopping breast feeding prior to the start of the study, 
- Use of hormonal contraceptives in a period of two months or less before the start of the 
experiment, 
- Use of IUD at the beginning of the study, 
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- Completely sedentary or extremely fit subjects, 
- Fractures or tendon laceration within one year, 
- History of genetic muscle and bone diseases of any kind. 
- Osteosynthesis material 
- Chronic back pains, 
- Past records of thrombophlebitis, 
- Presence of metallic implants, 
- Special food diet, 
- Refusal to give permission for her general practitioner to be informed of her participation in 
the trial, 
- Belonging to one of the following categories: incarcerated persons, patients in an emergency 
situation, 
- Unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator, or 
unable to cooperate because of a language problem, 





Assay Procedure Summaries 
Angiotensin II – SPI-BIO (#A05880) 
Sample Preparation 
1 Pre-wash phenyl cartridges with 1 ml of methanol, followed by 1 ml of water 
2 Pass 2 ml of plasma through the cartridge and then wash with 1 ml of water 
3 Elute absorbed Angiotensin peptides with 0.5 ml of methanol 
4 Evaporate methanol to dryness either by vacuum centrifugation or by evaporation under a 
stream of dry nitrogen 
5 Add 0.5 ml of Enzyme ImmunoAssay (EIA) buffer, vortex and centrifuge at 3000 g for 
10 min at +4oC 
Assay Procedure 
6 Prepare all reagents according to kit instructions 
7 Rinse plate five times with wash buffer (300 µl/well) 





















 Figure C.1 Plate setup for angiotensin II 






9 Add 100 µl of EIA buffer to Non-Specific Binding (NSB) wells 
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10 Add 100 µl of Angiotensin II standard to appropriate standard well (S1 to S8) 
11 Add 100 µl of Sample to appropriate wells (*) (at least in duplicate) 
12 Incubate for 1 h at room temperature with gentle agitation 
13 Add 50 µl of gluteraldehyde to each well (except blanks) and incubate for 5 min at room 
temperature with gentle agitation 
14 Add 50 µl of borane-trimethylamine to each well (except blanks) and incubate for 5 min 
at room temperature with gentle agitation 
15 Wash each well five times with wash buffer (300 µl/well)  
16 Add 100 µl of anti-Angiotensin II IgG tracer to each well (except blanks) 
17 Cover plate with plastic film and incubate overnight at +4oC 
18 Wash each well five times with wash buffer (300 µl/well) 
19 Add 300 µl of wash buffer and incubate for 10 min at room temperature with gentle 
agitation 
20 Wash each well five times with wash buffer (300 µl/well) 
21 Add 200 µl Ellman’s reagent (to all wells) and incubate in dark for 1 h on an orbital 
shaker 
22 Read plate between 405 and 414 nm (yellow colour) 
Endothelin-1 – R&D Systems (# BBE 5) 
Sample Preparation 
1 Add 1 ml of plasma and 1.5 ml of extraction solvent (acetone:1 N HCl:Water (40:1:5)) to 
a polypropylene tube 
2 Mix by inversion  
3 Centrifuge for 20 min at 2000 g at 2 – 80C 
4 Decant supernatant into polypropylene tube 
5 Dry down supernatant in centrifugal evaporator (min 4 h at 37oC) 
6 Reconstitute pellet in 0.25 ml sample diluent and vortex for 30 s 
7 Assay immediately or store reconstituted samples overnight at 2 – 8oC 
Assay Procedure  
8 Prepare all reagents according to kit instructions 
9 Add 100 µl of diluted Conjugate to each well 
10 Add 100 µl  of Standard, Control, or reconstituted sample to each well (in triplicate) 
11 Cover plate with a plate sealer provided and incubate at room temperature for 1 h 
12 Aspirate or decant contents of wells and wash six times with Wash Buffer 
13 Add 100 µl of Substrate to each well 
14 Cover plate with new plate sealer provided and incubate at room temperature for 1 h 
15 Add 100 µl of Stop Solution to each well 
16 Read plate at 450 nm with a wavelength correction set at 620 or 650 nm 
VCAM-1 – R&D Systems (#DVC00) 
Sample Preparation 
1 Dilute sample 20-fold (i.e. 20 µl sample + 380 µl Calibrator Diluent RD5P (1x) 
Assay procedure  
2 Prepare all reagents according to kit instructions 
3 Add 100 µl of sVCAM-1 Conjugate to each well 
4 Add 100 µl of Standard or diluted sample to each well (in triplicate) 
5 Cover plate with a plate sealer provided and incubate at room temperature for 1.5 h 
6 Aspirate or decant contents of wells and wash four times with Wash Buffer 
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7 Add 100 µl of Substrate to each well 
8 Cover plate with new plate sealer provided and incubate at room temperature for 20 min 
(Protect from light) 
9 Add 50 µl of Stop Solution to each well 
10 Read plate at 450 nm with a wavelength correction set at 540 or 570 nm 
11 Correct for dilution  
 
ICAM-1 – R&D Systems (#BBE 1B) 
Sample Preparation 
1 Dilute sample 20-fold (i.e. 15 µl sample + 285 µl Sample Diluent) 
Assay procedure  
2 Prepare all reagents according to kit instructions 
3 Add 100 µl of sICAM-1 Conjugate to each well 
4 Add 100 µl of Standard, Control or diluted sample to each well (in triplicate) 
5 Cover plate with a plate sealer provided and incubate at room temperature for 1.5 h 
6 Aspirate or decant contents of wells and wash six times with Wash Buffer 
7 Add 100 µl of Substrate to each well  
8 Cover plate with new plate sealer provided and incubate at room temperature for 30 min 
9 Add 100 µl of Stop Solution to each well 
10 Read plate at 450 nm with a wavelength correction set at 620 or 650 nm 
11 Correct for dilution  
E-Selectin – R&D Systems (#BBE 2B) 
Sample Preparation 
1 Dilute sample 20-fold (i.e. 25 µl sample + 475 µl Sample Diluent) 
Assay procedure  
2 Prepare all reagents according to kit instructions 
3 Add 100 µl  of sE-Selectin Conjugate to each well 
4 Add 100 µl  of Standard, Control or diluted sample to each well (in triplicate) 
5 Cover plate with a plate sealer provided and incubate at room temperature for 1.5 h 
6 Aspirate or decant contents of wells and wash six times with Wash Buffer 
7 Add 100 µl of Substrate to each well  
8 Cover plate with new plate sealer provided and incubate at room temperature for 30 min 
9 Add 100 µl of Stop Solution to each well 
10 Read plate at 450 nm with a wavelength correction set at 620 or 650 nm 
11 Correct for dilution  
CRP – ALPCO Diagnostics (#30-9710s) 
Sample Preparation 
1 Dilute sample 100 fold (i.e. 10 µl sample to 990 µl dilution buffer)  
Assay procedure  
2 Wash plate five times with wash buffer (250 µl/well) 
3 Prepare all reagents according to kit instructions 
4 Add 100 µl of calibrator and samples into each well (in triplicate) 
5 Incubate for 1 h shaking on a horizontal mixer at room temperature 
6 Aspirate and wash plate five times with wash buffer (250 µl/well) 
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7 Add 100 µl prediluted Peroxidase-labeled CRP antibody to each well 
8 Incubate for 1 h shaking on a horizontal mixer at room temperature 
9 Decant contents and wash plate five times with wash buffer (250 µl/well) 
10 Add 100 µl TMB substrate solution to each well 
11 Incubate for 5 to 10 min at room temperature in the dark 
12 Add 50 µl Stop Solution to each well and mix shortly 
13 Read plate at 450 nm 
14 Correct for dilution 
ADMA – ALPCO Diagnostics (#17-EA201/96) 
Sample Preparation (Acylation) 
1 Add 20 µl standard A – F, Control 1 & 2, and samples into appropriate wells of Reaction 
Plate 
2 Add 25 µl Acylation Buffer to all wells 
3 Add 25 µl Equalizing Reagent to all wells 
4 Mix reaction plate for 10 sec 
5 Prepare Acylation reagent freshly and add 25 µl to all wells, mix immediately 
6 Incubate for 30 min at room temperature on an orbital shaker 
7 Dilute 1.5 ml prepared Equalizing Reagent in 9 ml distilled water, mix and add 100 µl to 
each well 
8 Incubate for 45 min at room temperature on an orbital shaker 
Assay Procedure 
9 Remove 50 µl of prepared standard A – F, Control 1 & 2, and samples from the reaction 
plate and add it to corresponding well of the coated plate 
10 Add 50 µl of Antiserum into all wells and shake shortly on an orbital shaker 
11 Cover plate and incubate overnight at 2 to 8oC in the dark 
12 Aspirate or decant contents of wells and wash five times with wash buffer (250 µl/well) 
13 Add 100 µl enzyme conjugate into all wells 
14 Incubate for 60 min at room temperature on an orbital shaker 
15 Aspirate or decant contents of wells and wash five times with wash buffer (250 µl/well) 
16 Add 100 µl of Substrate into all wells and incubate for 20 to 30 min at room temperature 
on an orbital shaker 
17 Add 100 µl Stop Solution to all wells 
18 Read plate at 450 nm (with a reference between 570 and 650 nm) 
NO Metabolites 
Analysis was performed as aseptically as possible with all glassware, pipette tips, and syringes 
rinsed repeatedly with nitrogen-free water before and between uses.  Serial dilutions of high 
purity sodium nitrate obtained from BioShop Inc., (Burlington, ON. Canada, catalogue number – 
SON 001) were dissolved in nitrogen-free water to use as standards were made new each day.  
HPLC grade ethanol was obtained from Fisher Chemicals (Fairlawn, NJ, USA) was mixed 1:1 
with EDTA prepared plasma samples in microtubes stood at 4oC for 30min before being 
centrifuged at 14000g for 5min.  The supernatant was recovered and used for analysis.  Sample 
preparation was always preformed on the day of measurement.  A blank 2:1 ethanol and nitrogen-
free water was also prepared each day for analysis.  Blank, standard, or sample injection into a 
chamber containing 95oC vanadium (III) chloride from Sigma-Aldrich (St. Louis, MO, USA 
catalog number – 20827-2) saturated in 1M hydrochloric acid initiated the conversion of nitrate, 
nitrite, and S-nitrosocompounds to an acidic NO vapor.   
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After neutralization by bubbling through aqueous sodium hydroxide, the NO gas was 
passed through a 0.2µm pore size polypropylene filter from Whatman Inc. (Clifton, NJ, USA 
catalog number – 6725-5002) and reacted with ozone in a small reaction cell at a pressure ranging 
from 4-6mmHg.  Emission from electronically excited nitrogen dioxide, generated from the 
chemiluminescent reaction between NO and ozone, is in the red and near-infrared region of the 
electromagnetic spectrum, and was detected by a thermoelectrically cooled (-12oC) 
photomultiplier tube outfitted with an optical filter that transmits only wavelengths above 600nm, 
avoiding the detection of other compounds undergoing reaction with ozone and emitting light at 
shorter yet otherwise detectable wavelengths.   
A standard curve was established prior to and following injection of plasma samples on 
each day to ensure that the sensitivity of the analyzer remained constant.  All samples were 
analyzed using the calibration curve generated prior to collection.  Following calibration each 
day, a sample blank and the plasma samples were injected in triplicate.  If the triplicates were not 
consistent, replicates of the sample were injected until consistent peaks were observed.   
Norepinephrine  
Standard preparation 
A.   Concentrated standard 
1 Weigh 1 mg Norepinephrine, Epinephrine, Dopamine to make 5 ml with 0.5 PCA  
B.   Concentrated internal standard  
2 Weigh 5mg 3,4-dihydroxybenzylamine (DHBA) and add 0.1 PCA to make 5 ml  
Working standard 
3 To 955 µl 0.1 M PCA add 21.5 µl A and 21.5 µl B (from above), mix well 
4 To 976 µl 0.1 M PCA add 21.5 µl of the above mixture (#3) and mix well 
5 To 976 µl 0.1 M PCA add 21.5 µl of the above mixture (#4) and mix well 
Working internal standard 
6 To 968 µl 0.1 M PCA add 27 µl of B (from above), mix well 
7 To 968 µl 0.1 M PCA add 27 µl of above mixture (#6) and mix well 
8 To 968 µl0.1 M PCA add 27 µl of above mixture (#7) and mix well 
Sample preparation (extraction) 
9 To a 1.5 ml polypropylene tube add 10 mg acid washed alumina 
10 Add 400 µl 2.0 M tris + 2% EDTA, pH 8.7 (fresh weekly) 
11 Add 50 µl DHBA 
12 Add 1 ml EGTA/Glutathione plasma or 1 ml working internal standard to each tube 
13 Mix by inversion (avoid foaming) for 30 to 60 min 
14 Discard supernatant and wash 4 times with dH2O (ensure inside of tube is completely 
rinsed of plasma) 
15 Add 100 µl of 0.1 M PCA, vortex then centrifuge at 12000 g for 10 min at +4oC 
16 Transfer 90 µl of supernatant to vial for, analysis with Waters 2690 alliance HPLC 
Total Antioxidant Capacity – ALPCO Diagnostics (#30-5200) 
Reagent Preparation 
1 Reagent 1 is prepared by adding 5 ml of reaction buffer A and 10 µl of peroxide solution 
(this is dilution 1) 
2 Add 100 µl of dilution 1 to 4.9 ml of reaction buffer A (this is reagent 1) 
3 Reagent 2a is prepared by adding 5 ml of reaction buffer A + 100 µl of reaction buffer B 
+ 5 µl of enzyme solution 
4 Reagent 2b is prepared by adding 5 ml of reaction buffer A and 100 µl reaction buffer B 
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The reason for two reagent B is due to the fact that the self-absorption of the sample and 
the reaction products produced by the added hydrogen peroxide.  Therefore it is 
important to measure the sample with and without the addition of enzyme 
5 Add 10 µl of sample, calibrator and control into wells (in duplicate) 
6 Add 100 µl of reagent 1 
7 Incubate for 10 min at 37oC 
8 Add 100 µl of reagent 2a and reagent 2b respectively 
9 Incubate for 5 min at room temperature 
10 Add 50 µl of Stop Solution 
11 Read plate at 450 nm 
12 Calculate total aniox. capacity using the following equation: 
Calibrator OD
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